Akari Therapeutics
AKTX
19 hedge funds and large institutions have $1.29M invested in Akari Therapeutics in 2025 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 4 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
36% more funds holding
Funds holding: 14 → 19 (+5)
9% more capital invested
Capital invested by funds: $1.18M → $1.29M (+$105K)
8.87% more ownership
Funds ownership: 3.59% → 12.46% (+8.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$1.58M |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$179K |
| 3 |
Jane Street
New York
|
+$41.6K |
| 4 |
CAMG
CWA Asset Management Group
Naples,
Florida
|
+$31.9K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$28.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OFW
Omnia Family Wealth
Aventura,
Florida
|
-$28.7K |
| 2 |
VF
Virtu Financial
New York
|
-$22K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$20K |
| 4 |
ACM
Accent Capital Management
Centerville,
Ohio
|
-$2.9K |
| 5 |
EWA
EverSource Wealth Advisors
Birmingham,
Alabama
|
-$44 |
AKTX Hedge Fund Activity: Q4 2025 in Review
19 of the 8,281 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q4 2025, worth a combined $1.29M — up 8.9% from $1.18M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new AKTX positions and 4 closed out — a net gain of 5 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $1.58M. The largest seller was Omnia Family Wealth, exiting entirely with an estimated $28.7K sold.
- 19 institutional investors held Akari Therapeutics (AKTX) as of Q4 2025, up from 14 in Q3 2025.
- Funds reported $1.29M of Akari Therapeutics stock for Q4 2025, up 8.9% quarter-over-quarter.
- 9 funds opened new Akari Therapeutics positions in Q4 2025 and 4 closed out, a net change of +5 holders.
- The largest Akari Therapeutics buyer in Q4 2025 was Armistice Capital, an estimated $1.58M added.
- The largest Akari Therapeutics seller in Q4 2025 was Omnia Family Wealth, an estimated $28.7K sold.
Based on aggregated 13F filings for Q4 2025.